November 18, 2022
Horizon Therapeutics said on November 16 that it has completed the enrollment of its PIII clinical trial in Japan to evaluate teprotumumab, known as Tepezza in the US, for the treatment of active thyroid eye disease (TED). The PIII trial,...read more